You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
|
|---|---|
| Published in |
Nature Reviews Immunology, April 2015
|
| DOI | 10.1038/nri3823 |
| Pubmed ID | |
| Authors |
David Klatzmann, Abul K. Abbas |
| Abstract |
Depletion of regulatory T (TReg) cells in otherwise healthy individuals leads to multi-organ autoimmune disease and inflammation. This indicates that in a normal immune system, there are self-specific effector T cells that are ready to attack normal tissue if they are not restrained by TReg cells. The data imply that there is a balance between effector T cells and TReg cells in health and suggest a therapeutic potential of TReg cells in diseases in which this balance is altered. Proof-of-concept clinical trials, now supported by robust mechanistic studies, have shown that low-dose interleukin-2 specifically expands and activates TReg cell populations and thus can control autoimmune diseases and inflammation. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 33% |
| France | 1 | 11% |
| Ecuador | 1 | 11% |
| Brazil | 1 | 11% |
| Unknown | 3 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 451 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | <1% |
| Italy | 1 | <1% |
| Portugal | 1 | <1% |
| United Kingdom | 1 | <1% |
| Sweden | 1 | <1% |
| Unknown | 443 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 92 | 20% |
| Student > Ph. D. Student | 82 | 18% |
| Student > Master | 45 | 10% |
| Student > Bachelor | 37 | 8% |
| Other | 26 | 6% |
| Other | 78 | 17% |
| Unknown | 91 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 89 | 20% |
| Immunology and Microbiology | 86 | 19% |
| Agricultural and Biological Sciences | 75 | 17% |
| Biochemistry, Genetics and Molecular Biology | 46 | 10% |
| Engineering | 8 | 2% |
| Other | 46 | 10% |
| Unknown | 101 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 42. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2024.
All research outputs
#879,158
of 23,578,918 outputs
Outputs from Nature Reviews Immunology
#409
of 2,530 outputs
Outputs of similar age
#11,525
of 265,615 outputs
Outputs of similar age from Nature Reviews Immunology
#5
of 37 outputs
Altmetric has tracked 23,578,918 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,530 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.1. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,615 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.